Unveiling the landscape of m5C RNA methylation in lung cancer: From molecular mechanisms to therapeutic opportunities
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.153259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Xiaoyou Zhong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing, 210024, China. Electronic address: 18889589331@163.com. Hauptthemen laut MEDLINE: Lung Neoplasms, 5-Methylcytosine. Die Arbeit nennt 127 Literaturangaben. Gefördert von: Jiangsu Provincial Health Commission, Nanjing Medical University, Jiangsu Commission of Health.
Abstract (Originalsprache)
RNA methylation has emerged as a critical frontier in epitranscriptomics, with 5-methylcytosine (m5C) drawing particular attention for its multilayered roles in post-transcriptional gene regulation. Recent studies demonstrate that m5C modulates diverse biological processes by stabilizing RNA transcripts, promoting nuclear export, shaping translational efficiency, and orchestrating noncoding RNA function. Analogous to DNA methylation, m5C is dynamically reversible and governed by a finely tuned regulatory system composed of "writers" (such as the NSUN family and DNMT2/TRDMT1), "readers" (including YBX1 and ALYREF), and "erasers" (TET enzymes and ALKBH1), which collectively dictate its spatial and temporal distribution. In lung cancer, disruption of this regulatory axis is increasingly recognized as a driver of tumor phenotypic remodeling, metabolic adaptation, and immune evasion. Notably, writer enzymes such as NSUN2, NSUN4, and NSUN6 promote malignant progression by stabilizing oncogenic transcripts, enhancing translation, and rewiring metabolic networks. Meanwhile, reader proteins YBX1 and ALYREF maintain the stability of m5C-modified RNAs and activate proliferative and pro-invasive signaling pathways, including PI3K/AKT, mTOR, and Hippo/Wnt. In addition, m5C plays a pivotal role in shaping the tumor immune microenvironment and modulating immune checkpoint activity, thereby influencing the responsiveness and resistance of lung cancer to radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing, 210024, China. Electronic address: 18889589331@163.com.
- Department of Hematology and Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, 030000, China. Electronic address: 18035871339@163.com.
- Department of Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing, 210024, China.
- Department of Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing, 210024, China. Electronic address: fwfei1974@njmu.edu.cn.
- Department of Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing, 210024, China. Electronic address: linwang1988@njmu.edu.cn.
Förderung
- Jiangsu Provincial Health Commission
- Nanjing Medical University
- Jiangsu Commission of Health
- National Natural Science Foundation of China
Zitieren
APA
Zhong, X., Wang, W., Lv, J., Fan, W., & Wang, L. (2026). Unveiling the landscape of m5C RNA methylation in lung cancer: From molecular mechanisms to therapeutic opportunities. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.153259
Vancouver
Zhong X, Wang W, Lv J, Fan W, Wang L. Unveiling the landscape of m5C RNA methylation in lung cancer: From molecular mechanisms to therapeutic opportunities. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.153259
BibTeX
@article{Zhong2026,
author = {Zhong, Xiaoyou and Wang, Wenjing and Lv, Jiajia and Fan, Weifei and Wang, Lin},
title = {Unveiling the landscape of m5C RNA methylation in lung cancer: From molecular mechanisms to therapeutic opportunities},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.153259}
}
EUVIMED